ABOUT
MYELOID
At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies and unleash the power of myeloid cells in cancer.
Our proprietary ATAK™ platform is designed to designed to turn myeloid cells against tumors. These engineered cells find, recognize and penetrate tumors. These cells also prime other elements of the immune system, including T cells, thereby reinforcing the anti-tumor immune response, culminating in cancer eradication.
THE
Myeloid is powered by the discoveries of our founders – a group of world-leading scientists whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery.
We’re building a team of talented, driven scientists and other biotech industry experts to turn these discoveries into novel, life-saving treatments for people navigating life with cancer.
TEAM
LEADERSHIP
Chief Business Officer
Darren Braccia
MD, MPH
Chief Medical Officer
Michele Gerber
Board Director
Elaine Jones
PhD
President; Newpath Partners
Thomas Cahill
MD PhD
MBA, PhD
Chief Executive Officer
Daniel Getts
Co-Founder
Yuxiao Wang
PhD
FOUNDERS
MD Phil
Founder & Chair - Advisory Board
Siddhartha Mukherjee
Founder
Ronald Vale, PhD
FOUNDERS
LEADERSHIP
FOUNDERS
INVESTORS
SCIENTIFIC ADVISORY BOARD
Clinical Cell
Therapy Advisors
Immunology, Virology & Myeloid Cell Advisors